A feasibility study of 7, 10 and 14 days of IV treatment in bronchiec
Research type
Research Study
Full title
A feasibility study of 7 versus 10 and 14 days of intravenous therapy for the treatment of infective exacerbations of non-cystic fibrosis bronchiectasis
IRAS ID
128760
Contact name
Tim Harrison
Contact email
Research summary
Non-Cystic fribrosis bronchiectasis is a common chronic respiratory disease which can lead to numerous admissions for patients due to recurrent infections. When patients are admitted they are usually given intravenous antibiotics for 14 days, though there is no evidence to say that 14 days is the optimum length of treatment time. We plan to perform this pilot study to investigate if it is possible to give IV treatment for a shorter length of time, 7 and 10 days. We will firstly determine if patients are willing to have their treatment shortened and be discharged home and, if the treating physicians is prepared to stop treatment at a shortened time point i.e 7 or 10 days and discharge them home.
REC name
East Midlands - Derby Research Ethics Committee
REC reference
13/EM/0193
Date of REC Opinion
21 Jun 2013
REC opinion
Further Information Favourable Opinion